Federal funding has helped make my HIV undetectable and restored me to health. But I'm afraid funding for my medications will dry up during Trump's administration.

Weight trajectories differed significantly among patients with HIV during the first year of ART, with no associations observed between weight gain and type of ART regimen.

Gilead stock tumbled Wednesday on reports HHS could slash federal funding for HIV prevention, a staple in Gilead Sciences' ...

Dolutegravir plus lamivudine shows comparable efficacy and safety with standard-of-care three-drug regimen in patients with ...

In about three short months, the Trump administration took a wrecking ball to foreign aid, threatening millions of lives and ...

Explore diffuse large B-cell lymphoma — symptoms, causes, diagnosis, treatment options, and prevention. Learn about its types ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

PEPFAR, a global program to combat AIDS, faces an existential threat due to partisan politics, but Congress has an opportunity to reform the program and ensure its continued success.

Adults living with HIV in Malawi are more than twice as likely to also have dementia compared to those without HIV, according ...

Adults living with HIV in Malawi are more than twice as likely to also have dementia compared to those without HIV, according ...

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...